comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 21:09:47 - browse：54483

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How clinical AI models' predictive power can degrade over time

hotspot

WSS

What's changing in Medicare's open enrollment this year?

European regulators consider appeal over Amylyx ALS drug

European regulators recommend Amylyx's ALS drug be rejected

A revolution in caring for preterm infants

How should state employee insurance handle Wegovy?

Virtual care provider acquires bankrupt Pear's prescription apps

hotspot

comprehensive

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Researchers CRISPR chickens in bid to protect them from bird flu

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Guidelines to prevent youth baseball injuries need more muscle

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Medicare proposal to cover medical devices draws a mixed reaction

Takeaways from AdvaMed, the largest medical devices conference

Peter Hotez and the public health issue of online harassment

STAT Readout: Today's biotech news includes Sana and Amylyx

focus

Akero's treatment for NASH falls short in cirrhosis study

Nick Jonas talks about managing diabetes along with his career

European regulators recommend Amylyx's ALS drug be rejected

Editas, Vertex strike deal on CRISPR

How should state employee insurance handle Wegovy?

Editas, Vertex strike deal on CRISPR

focus

hotspot

entertainment

knowledge